News & Updates
Filter by Specialty:
Gemcitabine for IR-NMIBC tied to more recurrence vs BCG
Treatment-naive patients with immediate-risk (IR) nonmuscle-invasive bladder cancer (NMIBC) who received gemcitabine appear to have greater recurrence risk than those given Bacillus Calmette-Guerin (BCG). Both treatments, however, are effective against disease progression.
Gemcitabine for IR-NMIBC tied to more recurrence vs BCG
06 Jun 2025
BGF initiation after an exacerbation in COPD: Does timing matter?
Findings from the MITOS EROS+CP (US) study underscore the importance of prompt initiation of budesonide/glycopyrrolate/formoterol fumarate (BGF) following an exacerbation in patients with chronic obstructive pulmonary disease (COPD).
BGF initiation after an exacerbation in COPD: Does timing matter?
06 Jun 2025
Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC
A network meta-analysis (NMA) reports that the combination regimen comprising atezolizumab and bevacizumab appears to be better than other first-line systemic therapeutic alternatives for advanced hepatocellular carcinoma (HCC) in terms of providing a balance between overall survival (OS) benefit and quality of life (QoL) preservation.
